July 6, 2026
Ionis announced that they have completed enrollment of Cohort 1 in the Phase 3 clinical trial of ION582, REVEAL.
“Guided by input from the Angelman community, REVEAL was intentionally designed to evaluate obudanersen across a broad range of people living with Angelman syndrome, reflecting the real-world diversity of this condition. We are deeply grateful to the entire Angelman syndrome community, especially the participants and their families, whose partnership made this achievement possible.” – Holly Kordasiewicz, Ph.D., executive vice president, chief development officer, Ionis.
Individuals enrolled in REVEAL are assigned to study “Cohorts” based on their age.
While enrollment in Cohort 1 has been completed, participating sites continue to screen participants for Cohort 2.
